Cullinan starts FDA filing process for zipalertinib chemotherapy regimen
Cullinan Therapeutics began the FDA New Drug Application filing process for zipalertinib combined with platinum-based chemotherapy in untreated EGFR exon 20 insertion non-small cell lung cancer. The filing uses results from the Phase 3 REZILIENT3 study, where the combination improved median progression-free survival versus chemotherapy alone, according to the company. Cullinan expects to finish the submission by year-end 2026.
Why it matters
The filing starts the regulatory pathway for a potential first-line use of zipalertinib, but it is not an approval. A separate FDA review of zipalertinib alone has a target action date of February 27, 2027.
Key facts
- 1Cullinan initiated an FDA New Drug Application submission for zipalertinib with platinum-based chemotherapy in previously untreated locally advanced or metastatic EGFR exon 20 insertion NSCLC. globenewswire.com
- 2Cullinan expects to complete the submission by year-end 2026. globenewswire.com
- 3The Phase 3 REZILIENT3 trial achieved its main endpoint and showed a statistically significant improvement in median progression-free survival for the combination against chemotherapy alone. globenewswire.com
- 4Zipalertinib has FDA Breakthrough Therapy designation for previously treated locally advanced or metastatic EGFR ex20ins NSCLC. globenewswire.com
- 5Cullinan is eligible for $30 million and $100 million in milestones upon second-line and first-line U.S. regulatory approvals, respectively. globenewswire.com
Open questions
- Cullinan's expected completion timing is forward-looking, and FDA approval of either the combination regimen or monotherapy remains uncertain.
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.